GSK: story ‘unfair'

Share this article:
GlaxoSmithKline's director of CME took exception with a Wall Street Journal report on GSK-funded med ed.

The December 2006 article asserts that GSK paid for a series of lectures by doctors who favor universal screening and treatment of pregnant women for genital herpes (MM&M, January 2007), two contentious issues.

“Your article implies that the industry uses [CME] as a means to promote product; this unfairly taints the value that quality CME brings to healthcare professionals and to the patients,” wrote Bryan King, PharmD, director, GSK Center for Medical Education, in a letter to the editor.
GSK's Valtrex is not approved to prevent neonatal herpes in pregnant women.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...